Huang Yidong, Wu Yang, Zeng Li, Shan Wei, Huang Lugang
Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Oncol Lett. 2018 Aug;16(2):2195-2200. doi: 10.3892/ol.2018.8914. Epub 2018 Jun 6.
Human renal cell carcinoma (RCC) is the most common type of kidney malignancy in adults accounting for 2-3% of all adult malignancies. In China, RCC accounts for ~0.5% of all cancer-associated mortalities, ranking 16th among all cancer types. For early-stage RCC, surgery is the recommended treatment. Molecularly targeted therapy is the preferred first-line treatment for clear-cell RCC. However, more potential targets are required. MicroRNA-338-3p (miR-338-3p) functions as a tumor suppressor in various cancers, but has not been studied in RCC. Accordingly, the present study investigated the role of miR-338-3p of RCC. It was demonstrated that miR-338-3p was present at low levels in RCC tissues. Also, overexpression of miR-338-3p inhibited cell proliferation and promoted cell apoptosis, and downregulation of miR-338-3p promoted cell proliferation. The 3' untranslated region of AKT serine/threonine kinase 3 was targeted by miR-338-3p. In conclusion, the data of the present study revealed the inhibitory function of miR-338-3p in RCC and suggested that miR-338-3p is novel therapeutic target for RCC, but further investigation is needed.
人类肾细胞癌（RCC）是成人中最常见的肾脏恶性肿瘤类型，占所有成人恶性肿瘤的2%-3%。在中国，RCC占所有癌症相关死亡人数的约0.5%，在所有癌症类型中排名第16位。对于早期RCC，推荐的治疗方法是手术。分子靶向治疗是透明细胞RCC的首选一线治疗方法。然而，还需要更多潜在的靶点。微小RNA-338-3p（miR-338-3p）在多种癌症中发挥肿瘤抑制作用，但尚未在RCC中进行研究。因此，本研究调查了miR-338-3p在RCC中的作用。结果表明，miR-338-3p在RCC组织中的表达水平较低。此外，miR-338-3p的过表达抑制细胞增殖并促进细胞凋亡，而miR-338-3p的下调则促进细胞增殖。miR-338-3p靶向AKT丝氨酸/苏氨酸激酶3的3'非翻译区。总之，本研究的数据揭示了miR-338-3p在RCC中的抑制作用，并表明miR-338-3p是RCC的新型治疗靶点，但还需要进一步研究。
